Scinopharm Taiwan, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
March 20, 2020 at 04:42 am IST
Share
ScinoPharm Taiwan, Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was TWD 2,892.783 million compared to TWD 3,524.263 million a year ago. Operating income was TWD 266.854 million compared to TWD 558.412 million a year ago. Net income was TWD 216.656 million compared to TWD 442.978 million a year ago. Basic earnings per share was TWD 0.27 compared to TWD 0.56 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
